Clinical Trial Update: NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a neoantigen-based dendritic cell vaccine (NEOadjuvant) for ovarian cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Carcinoma

Drugs mentioned

• NEOadjuvant Dendritic Cell Vaccination

Snippet

Sponsor: Radboud University Medical Center | Conditions: Epithelial Ovarian Cancer, Ovarian Carcinoma | Phase 1, Phase 2 | Status: RECRUITING